344 related articles for article (PubMed ID: 26759276)
1. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.
Rugo HS; Hortobagyi GN; Yao J; Pavel M; Ravaud A; Franz D; Ringeisen F; Gallo J; Rouyrre N; Anak O; Motzer R
Ann Oncol; 2016 Mar; 27(3):519-25. PubMed ID: 26759276
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost MD; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Niolat J; Jóźwiak S
PLoS One; 2016; 11(6):e0158476. PubMed ID: 27351628
[TBL] [Abstract][Full Text] [Related]
3. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z
BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.
Jones VE; McIntyre KJ; Paul D; Wilks ST; Ondreyco SM; Sedlacek S; Melnyk A; Oommen SP; Wang Y; Peck SR; O'Shaughnessy JA
Oncologist; 2019 Sep; 24(9):1153-1158. PubMed ID: 30833486
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
[TBL] [Abstract][Full Text] [Related]
6. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
[TBL] [Abstract][Full Text] [Related]
8. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience.
Krueger DA; Capal JK; Curatolo P; Devinsky O; Ess K; Tzadok M; Koenig MK; Narayanan V; Ramos F; Jozwiak S; de Vries P; Jansen AC; Wong M; Mowat D; Lawson J; Bruns S; Franz DN;
Eur J Paediatr Neurol; 2018 Nov; 22(6):1066-1073. PubMed ID: 30005812
[TBL] [Abstract][Full Text] [Related]
9. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies.
Franz DN; Budde K; Kingswood JC; Belousova E; Sparagana S; de Vries PJ; Berkowitz N; Ridolfi A; Bissler JJ
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1796-1803. PubMed ID: 29569806
[TBL] [Abstract][Full Text] [Related]
10. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.
Samueli S; Abraham K; Dressler A; Gröppel G; Mühlebner-Fahrngruber A; Scholl T; Kasprian G; Laccone F; Feucht M
Orphanet J Rare Dis; 2016 Nov; 11(1):145. PubMed ID: 27809914
[TBL] [Abstract][Full Text] [Related]
12. Everolimus for advanced pancreatic neuroendocrine tumors.
Yao JC; Shah MH; Ito T; Bohas CL; Wolin EM; Van Cutsem E; Hobday TJ; Okusaka T; Capdevila J; de Vries EG; Tomassetti P; Pavel ME; Hoosen S; Haas T; Lincy J; Lebwohl D; Öberg K;
N Engl J Med; 2011 Feb; 364(6):514-23. PubMed ID: 21306238
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
Shameem R; Lacouture M; Wu S
Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
[TBL] [Abstract][Full Text] [Related]
14. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
15. Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Józwiak S; Stein K; Kotulska K
Future Oncol; 2012 Dec; 8(12):1515-23. PubMed ID: 23231513
[TBL] [Abstract][Full Text] [Related]
16. Management of side effects of mTOR inhibitors in tuberous sclerosis patients.
Sadowski K; Kotulska K; Jóźwiak S
Pharmacol Rep; 2016 Jun; 68(3):536-42. PubMed ID: 26891243
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer patients have increased risk of developing mTOR inhibitor-associated stomatitis.
de Lima M; Hajj G; de Lima V; Alves FA
Oral Dis; 2018 Mar; 24(1-2):207-209. PubMed ID: 29480592
[TBL] [Abstract][Full Text] [Related]
18. Everolimus.
Hasskarl J
Recent Results Cancer Res; 2018; 211():101-123. PubMed ID: 30069763
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
20. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
